10-Q: Imunon Reports Positive Topline Results from Phase II OVATION 2 Study and Provides Financial Update

Imunon, a clinical-stage biotechnology company, announced positive topline results from its Phase II OVATION 2 study of IMNN-001 in advanced ovarian cancer, along with a financial update for the third quarter of 2024.

Summary

• Imunon, a clinical-stage biotechnology company, has released its financial results for the third quarter of 2024, reporting a net loss of $4.8 million, compared to a net loss of $3.5 million for the same period in 2023.
• The company's research and development expenses increased to $3.3 million in Q3 2024, up from $2.0 million in Q3 2023, driven by costs associated with the OVATION 2 study and the PlaCCine vaccine trial.
• General and administrative expenses decreased to $1.7 million in Q3 2024, compared to $1.9 million in Q3 2023, primarily due to lower legal fees.
• Imunon reported positive topline results from its Phase II OVATION 2 study, showing an 11.1-month increase in median overall survival (OS) in the intent-to-treat (ITT) population compared to standard-of-care alone.
• The study also showed a 3-month improvement in progression-free survival (PFS) compared to standard-of-care alone.
• The company completed enrollment in the OVATION 2 study with 113 patients and has scheduled an End-of-Phase II meeting with the FDA in the fourth quarter of 2024.
• Imunon also received FDA clearance to begin a Phase I clinical trial for its seasonal COVID-19 booster vaccine, IMNN-101, and has completed enrollment of 24 participants with topline data expected by year-end 2024.
• As of September 30, 2024, Imunon had $10.3 million in cash and cash equivalents, and management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company raised $10 million in gross proceeds through a registered direct offering in July 2024, issuing 5,000,000 shares of common stock at $2.00 per share, along with warrants to purchase an additional 5,000,000 shares.

Sentiment

Score: 6

Explanation: The document presents positive clinical trial results, particularly the increase in overall survival in the OVATION 2 study, which is a significant positive. However, the company's financial situation and going concern warning temper the overall sentiment. The successful capital raise is a positive, but the need for further funding and the inherent risks of drug development keep the sentiment from being overly optimistic.

Positives

• The OVATION 2 study demonstrated a significant increase in overall survival for patients treated with IMNN-001.
• The study showed a positive trend in progression-free survival for patients treated with IMNN-001.
• The company has received FDA clearance to begin a Phase I clinical trial for its COVID-19 booster vaccine.
• Imunon successfully raised $10 million through a registered direct offering, providing additional capital for operations.

Negatives

• The company reported a net loss of $4.8 million for the third quarter of 2024, an increase from $3.5 million in the same period of 2023.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to its financial condition.
• The company's cash and cash equivalents stood at $10.3 million as of September 30, 2024, which may not be sufficient to fund operations for the next twelve months.

Risks

• The company's ability to continue as a going concern is uncertain due to its substantial operating losses and limited cash reserves.
• The company's ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and volatility in financial markets.
• There is no assurance that the company will be able to secure additional funding on favorable terms or at all.
• The company's future success depends on the successful development and commercialization of its drug candidates, which is subject to inherent risks and uncertainties.

Future Outlook

The company plans to present full OVATION 2 Study results at an upcoming medical conference and to submit the results for publication in a peer-reviewed medical journal. The EOP2 meeting with the FDA is scheduled for the fourth quarter of 2024, and the Phase 3 trial is anticipated to begin in the first quarter of 2025. The company also intends to seek partnership and/or business development opportunities to develop future the scientific and business case for IMNN-101 as a future vaccine to address viral mutations.

Management Comments

• Management has determined there is substantial doubt regarding our ability to continue as a going concern.
• Management's plan may include raising funds from outside investors via its ATM program and other potential funding sources.

Industry Context

The positive results from the OVATION 2 study are significant in the context of the ovarian cancer treatment landscape, where there is a need for therapies that improve overall survival. The development of a COVID-19 booster vaccine also aligns with the ongoing global efforts to combat the pandemic. The company's focus on DNA-based therapeutics and vaccines positions it within the broader trend of innovative approaches in biotechnology.

Comparison to Industry Standards

• The reported 11.1-month increase in median overall survival in the OVATION 2 study is a notable improvement compared to standard-of-care treatments for advanced ovarian cancer, which typically have a median OS of around 30-40 months.
• The hazard ratio of 0.74 in the ITT population suggests a significant reduction in the risk of death, which is a positive outcome compared to many other clinical trials in this space.
• The 3-month improvement in PFS is also a clinically meaningful result, as it indicates a delay in disease progression, which is a key goal in cancer treatment.
• The company's focus on a DNA-based vaccine platform is a novel approach compared to the more common mRNA vaccines, and the results from the NHP study suggest that it could be a viable alternative.
• The company's approach to targeting multiple antigens on a single plasmid vector for its COVID-19 vaccine is a unique strategy that could potentially address viral mutations more effectively than single-antigen vaccines.

Management Changes

Legal Proceedings

• In June 2024, the U.S. District Court issued an Order for Dismissal without prejudice for a derivative shareholder lawsuit.

Related Party Transactions

• On November 16, 2022 the Company entered into a convertible note purchase agreement with Transomic Technologies, Inc. (Transomic) whereby the Company purchased $ 375,000 of convertible notes secured by certain assets held by Transomic and warrants.
• In December 2023, Transomic filed a formal certificate of dissolution of the company resulting in a complete write-off of the convertible note and related warrants.

Stakeholder Impact

• Shareholders may be concerned about the company's going concern status, but encouraged by the positive clinical trial results.
• Employees may be affected by potential cost-cutting measures or changes in the company's direction.
• Patients may benefit from the potential approval of IMNN-001 and the COVID-19 vaccine.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to present full OVATION 2 Study results at an upcoming medical conference and to submit the results for publication in a peer-reviewed medical journal.
• The company will have an End-of-Phase II (EOP2) meeting with the FDA in the fourth quarter of 2024.
• The company anticipates beginning a Phase 3 trial in the first quarter of 2025.
• The company intends to seek partnership and/or business development opportunities to develop future the scientific and business case for IMNN-101 as a future vaccine to address viral mutations.

Key Dates

Keywords

IMNN-001, Ovarian Cancer, Immunotherapy, Phase II Trial, OVATION 2 Study, COVID-19 Vaccine, IMNN-101, Clinical Trial, Biotechnology, TheraPlas, PlaCCine, FDA, Capital Raise, Going Concern